Pharmacokinetics, Safety, and Clinical Efficacy of Cannabidiol Treatment in Osteoarthritic Dogs.

Spread the love

Gamble LJ1, Boesch JM1, Frye CW1, Schwark WS2, Mann S3, Wolfe L4, Brown H5, Berthelsen ES1, Wakshlag JJ1.Author information1Department of Clinical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY, United States.2Department of Molecular Medicine, College of Veterinary Medicine, Cornell University, Ithaca, NY, United States.3Department of Population Medicine, College of Veterinary Medicine, Cornell University, Ithaca, NY, United States.4Proteomic and Metabolomic Facility, Colorado State University, Fort Collins, CO, United States.5Metzger Animal Hospital, State College, PA, United States.Abstract

Objectives: The objectives of this study were to determine basic oral pharmacokinetics, and assess safety and analgesic efficacy of a cannabidiol (CBD) based oil in dogs with osteoarthritis (OA). Methods: Single-dose pharmacokinetics was performed using two different doses of CBD enriched (2 and 8 mg/kg) oil. Thereafter, a randomized placebo-controlled, veterinarian, and owner blinded, cross-over study was conducted. Dogs received each of two treatments: CBD oil (2 mg/kg) or placebo oil every 12 h. Each treatment lasted for 4 weeks with a 2-week washout period. Baseline veterinary assessment and owner questionnaires were completed before initiating each treatment and at weeks 2 and 4. Hematology, serum chemistry and physical examinations were performed at each visit. A mixed model analysis, analyzing the change from enrollment baseline for all other time points was utilized for all variables of interest, with a p

View the Original article

Laissez un commentaire

Votre adresse de messagerie ne sera pas publiée. Les champs obligatoires sont indiqués avec *

Ce site utilise Akismet pour réduire les indésirables. En savoir plus sur comment les données de vos commentaires sont utilisées.

error: Content is protected !!
%d blogueurs aiment cette page :